期刊文献+

荧光原位杂交技术在尿路上皮癌诊断中的应用 被引量:2

Application of fluorescence in situ hybridization in the diagnosis of urothelial carcinoma
原文传递
导出
摘要 目的探讨荧光原位杂交技术(FISH)在尿路上皮癌诊断中的应用价值。方法采用FISH检测100例血尿患者尿脱落细胞中第3、7、17号染色体和第9号染色体p16位点异常,以组织病理学确诊尿路上皮癌为金标准,评估FISH诊断的敏感度和特异度,并与尿细胞学检查结果进行比较。结果FISH检测和尿细胞学检查诊断尿路上皮癌的敏感度分别为82.5%和49.2%,差异有统计学意义(P〈0.05);特异度分别为86.7%和96.6%,差异无统计学意义(P〉0.05)。结论与尿细胞学比较,FISH诊断尿路上皮癌具有较高的敏感度和相似的特异度。 Objective To evaluate the results of fluorescence in situ hybridization (FISH) for detecting urothehal carcinoma. Methods Voided urine samples from 100 patients with haematuria were analyzed by FISH and cytology; labeled probes for chromosomes 3,7,17 and 9 p16 were used to assess chromosomal abnormalities. The gold standard was pathology diagnosis. The overall sensitivity and specificity of FISH were evaluated and compared with cytology. Results The sensitivity of FISH and cytology in detection urothelial cancer were 82. 5% and 49. 2% respectively,and the specificity was 86.7% and 96. 6% respectively. There was a significant difference between the sensitivity( P 〈0. 05 ) ,and the different between the specificity was not significant ( P 〉 0.05 ). Conclusion Compared with urine cytology, FISH diagnosis of urothelial carcinoma with high sensitivity and a similar specificity.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2012年第6期1028-1030,共3页 Chinese Journal of Experimental Surgery
基金 中华医学会分子生物学临床应用研究专项基金项目(CAMB032010)
关键词 荧光原位杂交 尿路上皮癌 尿细胞学 Fluorescence in situ hybridization Urothelial carcinoma Cytology
  • 相关文献

参考文献17

  • 1van Rhijn BW,van der Poel HG,van der Kwast TH. Urinemarkers for bladder cancer surveillance : a systematic review. Eur Urol, 2005,47 : 736-748.
  • 2Sokolova IA, Halling KC, Jenkins RB, et al. The development of a muhitarget,multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn, 2000,2 : 116- 123.
  • 3Stewart GD,Bariol SV,Grigor KM,et al. A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU Int,2005,95:791-793.
  • 4Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin,2005,55:74-108.
  • 5李振华,王毅,杨春明,孔垂泽,王立忠.尿液脱落细胞HER-2/neu基因扩增/17号染色体多倍体在尿路上皮癌诊治中的意义[J].中华实验外科杂志,2004,21(4):510-510. 被引量:1
  • 6Sandberg AA, Berger CS. Review of chromosome studies in urological tumors. Ⅱ. Cytogenetics and molecular genetics of bladder cancer. J Urol, 1994,151:545-560.
  • 7Kruger S, Mess F, Bohle A, et al. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Onco1,2003,23:41-48.
  • 8Sauter G, Haley J, Chew K, et al. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer,1994,57:508-514.
  • 9Ribal M J, Alcaraz A, Mengual L, et al. Chromosomal high-polysomies predict tumour progression in T1 transitional cell carcinoma of the bladder. Eur Uro1,2004 ,45 :593-599.
  • 10Fadl-Elmula I, Gorunova L, Mandahl N, et al. Cytogenetic analysis of upper urinary tract transitional cell carcinomas. Cancer Genet Cytogenet, 1999,115:123-127.

二级参考文献3

  • 1Halling KC,King W,Sokolova IA,et al.A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma[].Journal d Urologie.2000
  • 2Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[].The New England Journal of Medicine.2001
  • 3Tubbs RR,Pettay JD,Roche PC,et al.Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false postitives do not get the message[].Journal of Clinical Oncology.2001

共引文献8

同被引文献18

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部